FDA clears Xoft's Axxent for breast cancer

Jan. 4, 2006 at 1:14 PM
share with facebook
share with twitter

FREMONT, Calif., Jan. 4 (UPI) -- Xoft said Wednesday it has been cleared to market its Axxent Electronic Brachytherapy System for breast cancer.

The Axxent system uses non-radioactive sources to deliver radiation treatment, which eliminates the need for heavily shielded environments and may enable the therapy to be used in more clinical settings.

"This may accelerate patient choice of breast sparing lumpectomy surgery with adjuvant radiation therapy over the alternative of a full mastectomy," Xoft said in a statement.

"As electronic brachytherapy now moves into clinical practice, all indications are that this technology represents a leap forward in cancer treatment," Dr. Kambiz Dowlat, a professor of surgery at Rush University Medical Center in Chicago, said in a statement released by Xoft.

"However, as important as the clinical benefits are, the true breakthrough may relate to easy and convenient access to non-radioactive brachytherapy for women who today opt for mastectomy or lumpectomy without radiation therapy," Dowlat added.

Trending Stories